Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after ...

Cardioprotective Effects of Selective Aldosterone Blockade in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) - Medscape - Jun 25, 2004.

Finally, as COVID-19 has a strong component of ACE2 depletion underlying the course of the illness, and as RAAS (angiotensin and aldosterone) stressors promote cytokine-mediated disease in the lungs ...

Hyperkalaemia is a well-known complication of RAAS blockade due to inhibition of aldosterone production and its effect. [15, 17, 18, 24, 25] At 12 months in the HEAAL trial, serum potassium ...

Pune, Jan. 09, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Heart Failure Market by Type (Acute Heart Failure and Chronic Heart Failure) and by Therapeutic Drugs ...

Consider aldosterone antagonists for all patients with EF <35%, NYHA class III-IV with moderate-to-severe symptoms, and after optimal dose of beta blocker and ACE inhibitor or ARB.

Aldosterone blockers like spironolactone (a diuretic) and eplerenone (used mostly for heart failure) also increase potassium levels, as do angiotensin receptor blockers (drugs whose names end in ...

PHILADELPHIA—A novel selective aldosterone synthase (AS) inhibitor, BI690517, may improve the therapeutic ability to slow chronic kidney disease (CKD) progression, an investigator reported at ...

The primary outcome was optimal triple therapy GDMT, defined as concurrent administration of a renin-angiotensin aldosterone blocker and beta-blocker at 50% of the target dose and a ...